Brought to you by

Amgen buys its partner, Micromet, for over $1bn
27 Jan 2012
Executive Summary
Amgen Inc. has agreed to acquire Micromet Inc. (therapeutic antibodies) for $11 per share (a 29% premium), for a total of $1.01bn.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com